Abstract
The safety and effectiveness of biologic therapy in elderly IBD patients are not well established. This retrospective European study analyzed clinical outcomes in patients aged over 65 years receiving biologics. Clinical remission was achieved in a substantial proportion of patients, although infection risk was higher than in younger cohorts. Careful patient selection and monitoring are essential in this population.
